Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Medicine Matters oncology

Immune checkpoint inhibitors, specifically those targeting PD-1, are promising candidates for treatment of advanced-stage CTCL. In a phase II, single-arm study, pembrolizumab (Keytruda®) demonstrated an overall RR of 38% in pretreated patients with MF and SS [19]. PD-1 inhibitors are generally well-tolerated with some immune-related toxicities. Due to their relatively good safety profiles, multiple clinical trials are underway investigating PD-1 inhibitors in combination with radiotherapy, romidepsin, or decitabine and pralatrexate in CTCL.